---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-25-000021"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:59:41.510205+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SELLAS Q3 net loss $6.8M ($0.06/sh); cash $44.3M plus $29.1M warrant proceeds in Oct

## Summary
- Net loss of $6.8M ($0.06 diluted EPS) vs $7.1M ($0.10) a year ago; nine-month loss $19.2M ($0.20).
- Cash and equivalents $44.3M at Sep 30, 2025; additional $29.1M net from warrant exercises in October.
- Phase 3 REGAL trial of GPS in AML CR2 final analysis expected by year-end 2025 (80 events).
- Phase 2 SLS009 in R/R AML data accepted for ASH 2025; trial in first-line AML to start Q1 2026.
- R&D expense $4.2M (down 5% YoY); G&A expense $2.9M (down 3% YoY).

## SEC filing metadata
- accession: 0001390478-25-000021
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/0001390478-25-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/sls-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-25-000021
- JSON: https://secwatch.observer/filing/0001390478-25-000021.json
- Plain text: https://secwatch.observer/filing/0001390478-25-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.